

IDMA BULLETIN

VOL. NO. 53

ISSUE NO. 46 (PAGES: 20)

08 TO 14 DECEMBER 2022

ISSN 0970-6054

WEEKLY PUBLICATION



INDIAN PHARMA - GLOBAL HEALTH CARE

INDIAN DRUG MANUFACTURERS' ASSOCIATION

Block
your
Date

IDMA has pleasure in announcing the much awaited
22nd IDMA – APA Pharmaceutical Analysts' Convention (PAC) 2023
Along with EDQM (European Directorate for the
Quality of Medicines & HealthCare)

On

Friday, 24th February and Saturday, 25th February, 2023

Please await further details

HIGHLIGHTS

- ★ **Invitation For Pharma Conclave to be held on 8th January 2023 in association with BAPS, Swaminarayan Sanstha at Ahmedabad**
(Page No. 4)
- ★ **Inclusion of additional export items in Appendix 4R under RoDTEP with effect from 15.12.2022** (Page No. 8)
- ★ **Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012 Amended (1st Amendment of 2022)** (Page No. 8)

**'EXACT' IS A SCIENCE.
AND AN ART. THAT'S
ACCURACY FOR US.**



Dear Partner,

We serve a multitude of clients, fulfilling just as many needs along the way. And in spite of variables, we have been tremendously accurate in doing so. This wouldn't be possible without partners like Asahi Kasei, Morimura and Mitsubishi Chemical Corporation.

Specialists in the production of microcrystalline cellulose spheres and pregelatinized starch, Asahi Kasei is renowned for their meticulous and forward-thinking approach. Morimura brings their tremendous experience of over 140 years in supplying a top quality plasticiser that is used for a host of pharmaceutical applications.

While Mitsubishi Chemical Corporation is the foremost name in the production of highly refined sucrose fatty acid esters (non-ionic emulsifiers) that meets the highest global standards.

We truly believe in the accuracy of information and guidance offered by Asahi Kasei, Morimura and Mitsubishi Chemical Corporation. As should you. For that's how we ensure the very same for you.

**Signet-ure
ACCURACY**



AsahiKASEI

CELPHERE

- Microcrystalline Cellulose Spheres

PC-10

- Partly Pregelatinized Corn Starch

SWELSTAR

- Pregelatinized Potato Starch



MORIMURA BROS., INC.

CITROFLEX

- Triethyl Citrate

MITSUBISHI-CHEMICAL CORPORATION

- SURFHOPE SE PHARMA
• Sucrose Stearate

Signet

The Complete Excipients Company



Founder Editor:
Dr. A. Patani

Editor:
Dr. Gopakumar G. Nair

Associate Editors:
Mr. J. L. Sipahimalani
Dr. Nagaraj Rao
Dr. George Patani

National President
Dr. Viranchi Shah

Immediate Past National President
Mr. Mahesh Doshi

Senior Vice-President
Mr. Bharat N Shah

Vice-Presidents:
Dr. George Patani
(Western Region)

Mr. Asheesh Roy
(Eastern Region)

Mr. B K Gupta
(Northern Region)

Mr. T Ravichandiran
(Southern Region)

Hon General Secretary
Mr. Mehul Shah

Hon Joint Secretaries
Mr. Kamlesh C Patel
Mr. Pranav Choksi

Hon Treasurer
Mr. Vinay Pinto

For information contact :
IDMA Secretariat: (H.O.)

Daara B Patel
Secretary-General

Melvin Rodrigues
Sr Manager (Commercial & Administration)

IDMA State Boards	Chairman
▶ Gujarat State Board	: Dr. Shrenik K Shah
▶ Haryana State Board	: P K Gupta
▶ Himachal Pradesh & Uttarakhand State Board	: R C Juneja
▶ Karnataka State Board	: S M Mudda
▶ Madhya Pradesh State Board	: Paresh Chawla
▶ Tamil Nadu, Puducherry & Kerala State Board	: J Jayaseelan
▶ Telangana State Board	: Shaik Janimiya
▶ West Bengal State Board	: Shiv Sagar Tewari
IDMA Delhi Office	: Ashok Kumar Madan Executive Director
	: S. Ranganathan Asst. Manager (Administration)

A Publication of
Indian Drug Manufacturers' Association
102-B, 'A-Wing', Poonam Chambers,
Dr. A.B. Road, Worli, Mumbai - 400 018
Tel : 022-2494 4624 / 2497 4308 Fax: 022-2495 0723
e-mail: publications@idmaindia.com/
actadm@idmaindia.com/ website: www.idma-assn.org

Published on 7th, 14th, 21st and 30th of every month

Annual Subscription
₹ 1000/- (for IDMA members)
₹ 2000/- (for Government Research/Educational Institutions)
₹ 4000/- (for non-members) US\$ 400 (Overseas)
Please send your payment in favour of
Indian Drug Manufacturers' Association

OPINIONS EXPRESSED BY THE AUTHORS OF INDIVIDUAL ARTICLES
DO NOT NECESSARILY REPRESENT THE OFFICIAL VIEW OF IDMA.

IDMA BULLETIN

Vol. No. 53 Issue No. 46 08 to 14 December 2022

IDMA ACTIVITIES:

Invitation For Pharma Conclave to be held on 8th January 2023 in association with BAPS, Swaminarayan Sanstha at Ahmedabad 4

GOVERNMENT COMMUNICATION:

Official Notification UPCI.416.22.2050 regarding review of the validity of the antidumping duty imposed on imports of Amoxicillin trihydrate originating in the Republic of India 7

GOVERNMENT NOTIFICATIONS:

Inclusion of additional export items in Appendix 4R under RoDTEP with effect from 15.12.2022 - reg 8

Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012 Amended (1st Amendment of 2022) 8

PARLIAMENT NEWS:

In Lok Sabha & In Rajya Sabha 9

NATIONAL NEWS:

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand 15

Saudi Arabia invites Indian cos to supply 300 life-saving drugs in therapeutic segments like AIDS, TB, BP, etc 16

Goyal meets UK trade secy to give momentum to FTA talks 16

.....
IDMA Bulletin tariff card..... 18

.....
Advertisements..... 2, 19 & 20



INDIAN DRUG MANUFACTURERS' ASSOCIATION (IDMA)

102, Poonam Chambers, A Wing, 1st Floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018. Maharashtra, India.
Tel: +91-22-24974308 / 24944624 E-mail: actadm@idmaindia.com Website: www.idma-assn.org

Invitation For Pharma Conclave to be held on 8th January 2023 in association with BAPS, Swaminarayan Sanstha at Ahmedabad

Dear Member,

It gives us great pleasure to invite all members of "Pharma industry to participate" in "Pharma Conclave"- a special 1 day conference to be held in association with "BAPS" Swaminarayan Sanstha at Pramukh Swami Nagar on Sunday, 8th January, 2023. The conclave is organised in association with *GCCCI, DMMA, GCA, GPA, FGSCDA, GAAMA, IPMMA, NDIA, Pharmexcil and other leading associations. BAPS Swaminarayan Sanstha is celebrating Pramukh Swami Maharaj's Centenary from 15th December 2022 to 15th January 2023 at Pramukh Swami Nagar, Sardar Patel Ring Road, Ahmedabad.

BAPS has invited IDMA to organize a one-day conference at the 600-acre Pramukh Swami Nagar festival site. The conference will feature talks and presentations by our leading members on most recent topics followed by enlightening talks from BAPS Sadhus.

A "personal guided" tour for all our esteemed members to the sprawling festival site has also been arranged. The Pramukh Swami Nagar comprises of several exhibition pavilions on life values, children's adventure land, light & sound show, thematic glow gardens, cultural gates, Pramukh Swami Maharaj's maha-murti, a replica of Swaminarayan Akshardham in New Delhi amongst other inspiring attractions.

Members are requested for their active participation.

Thanks & Regards,

Daara B. Patel

Secretary - General

IDMA

Indian Drugs Manufacturers' Association



PHARMA CONCLAVE

8th Jan 2023

Pramukh Swami Maharaj Nagar, Nr. Ognaj Circle, SP Ring Rd, Ahmedabad

CONFERENCE THEME: NICHE-THE GROWTH STRATEGY

08:30 AM TO 9:15 AM	REGISTRATION & BREAKFAST	12:15 PM TO 12:45 PM	DR. DUSHYANT PATEL- FOUNDER ASTRAL STERITECH PVT LTD
09:15 AM TO 09:45 AM	IDMA GSB AGM	12:45 PM TO 01:00 PM	Q&A
09:45 AM TO 10:45 AM	INAUGURAL FUNCTION: KEY NOTE ADDRESS BY SHRI PANKAJBHAI PATEL, CHAIRMAN ZYDUS ADDRESS BY MINISTER	01:00 PM TO 01:15 PM	VIDEO OF THE MAKING OF PRAMUKH SWAMI NAGAR
10:45 AM TO 11:15 AM	SHRI AMAN MEHTA- DIRECTOR TORRENT PHARMACEUTICALS LTD.	01:15 PM TO 02:00 PM	ADDRESS BY DR GYANVATSAL SWAMIJI ON "BEHIND THE SCENE-MANAGEMENT LEARNINGS"
11:15 AM TO 11:45 AM	MS ADITI KARE - MD INDOCO REMEDIES LTD	02:00 PM TO 03:00 PM	LUNCH
11:45 AM TO 12:15 PM	TEA BREAK	03:00 PM TO 07:00 PM	GUIDED TOUR OF PRAMUKH SWAMI NAGAR BY BAPS VOLUNTEERS
		07:00 PM ONWARDS	DINNER

SUPPORTING ASSOCIATIONS



Gujarat Chamber of Commerce & Industry



Federation of Gujarat State Chemist and Druggist Association



Drugs Marketing & Manufacturing Association



Gujarat Ayurvedic Aushadh Manufacturer's Association



Gujarat Chemical Association



Gujarat Pharmaceutical Association



Pharmaceutical Export Promotion Council



Indian Pharma Machinery Manufacturers Association



Nutraceuticals & Dietary Supplements Industries Aid Association

Registration link will open soon



EVENT CO-ORDINATOR

PHARMA

LIVE • EXPO 2023

Pharma Live Expo & Summit 2023
www.pharmaliveexpo.com

PHARMA CONCLAVE

8th Jan 2023

Pramukh Swami Maharaj Nagar, Nr. Ognaj Circle, SP Ring Rd, Ahmedabad

CONFERENCE THEME: NICHE-THE GROWTH STRATEGY

SPEAKERS



SHRI PANKAJBHAI PATEL



SHRI AMAN MEHTA



PUJYA DR GYANVATSAL SWAMI



MS ADITI KARE



DR. DUSHYANT PATEL

ORGANISING COMMITTEE

DR. VIRANCHI SHAH - NATIONAL PRESIDENT IDMA
DR. SHRENIK SHAH - CHAIRMAN, IDMA GSB
SHRI PATHIK PATWARI - PRESIDENT, GCCI
SHRI JASVANT PATEL - PRESIDENT, FGSCDA
DR JAIMIN VASA - PRESIDENT, GCA & GPA

SHRI AMIT THAKKAR - PRESIDENT, DMMA
SHRI JAMAN MALVIA - PRESIDENT, GAAMA
SHRI NITIN PANCHAL - PRESIDENT, NDIA
SHRI HARSHIT SHAH - PRESIDENT, IPMMA
SHRI KAMLESH PATEL
SHRI JAY PATEL
MS JINKAL PATEL
SHRI DAARA PATEL
SHRI SANCHIT CHATURVEDI
SHRI SANJAY SHAH

SHRI MEHUL SHAH - HON. SECRETARY IDMA
SHRI SUMIT AGRAWAL - HON. SECRETARY IDMA GSB
SHRI ANIL JAIN - HON. SECRETARY GCCI
SHRI KIRIT PALAN - HON. SECRETARY FGSCDA
SHRI JIGNESH SHAH - HON. SECRETARY, GCA
SHRI MAYUR PARIKH - HON. SECRETARY, GPA
SHRI VIKRAM CHANDWANI - HON. SECRETARY, DMMA
SHRI DHANANJAY SHUKLA - HON. SECRETARY, GAAMA
SHRI NIKHIL KANSARA - HON. SECRETARY, NDIA
SHRI OSWIN D'SOUZA - HON. SECRETARY, IPMMA
SHRI NIRAV MEHTA
SHRI ATUL SHAH
SHRI MAULIK SHAH
SHRI CHIRAG DOSHI
SHRI VIJAY SHAH
SHRI RAJ SANGHAVI

Registration link will open soon



EVENT CO-ORDINATOR
PHARMA
LIVE•EXPO 2023

Pharma Live Expo & Summit 2023
www.pharmaliveexpo.com

Official Notification UPCI.416.22.2050 regarding review of the validity of the antidumping duty imposed on imports of Amoxicillin trihydrate originating in the Republic of India

Dated 7th December 2022

IDMA have received a communication from Mr Udaya Bhaskar, Director General, Pharmexcil dated 07th December 2022 on the above subject as reproduced below.

Dear Sir,

We are in receipt of communication from Indian Embassy, Mexico that the International Trade Practices Unit of the Ministry of Economy of Mexico, notified the Government of India of the official notification UPCI.416.22.2050 dated 24 November 2022 and published in their Official Gazette

1. The notification refers to *"Resolution declaring the initiation of the administrative proceeding for the review of the validity of the antidumping duty imposed on imports of amoxicillin trihydrate originating in the Republic of India, regardless of the country of origin.*
2. In this regard, it may kindly be noted that for the timely defense of our interests, should the Government of India decide to participate in this investigation, it is necessary to submit the required information and present our expression of interest for **submitting representation and arguments by 17 January 2023**, and that the deadline for submitting **counter-arguments is 27 January 2023**, failing which, India shall not be considered as an accredited party in this investigation, and that, the right to submit it at a later time shall be deemed precluded.

3. The original documents in Spanish, along with their translated versions are being attached.

We request you to convey this information to all concerned parties/entities from your organisation who would have an interest in the investigation.

We need to evaluate the position of India in terms of participation in Investigation and **request you to share the comments/inputs from your member companies required for the submission of arguments by Govt of India at the earliest (not later than 30th Dec 2022) to regulatory@pharmexcil.com.**

[Attachment 1: Resolution declaring the initiation of the administrative procedure for the review of the validity of the countervailing duty imposed on imports of amoxicillin trihydrate originating in the Republic of India, irrespective of the country of origin.](#)

[Attachment 2: Exporters Investigation for price discrimination](#)

[Attachment 3: Consent To Consultation of Information](#)

[Attachment 4: Consent To Receive Information And Notifications Electronically](#)

[Attachment 5: Evidence of Submission of Reports, Evidence And Documents](#)

[Attachment 6: Notification of Resolution of Initiation](#)



Inclusion of additional export items in Appendix 4R under RoDTEP with effect from 15.12.2022 - reg

Notification No: S.O.(E) 47/2015-2020, dated 07th December, 2022

1. In exercise of the powers conferred by Section 5 of the Foreign Trade (Development and Regulation) Act, 1992 read with Para 1.02 of the Foreign Trade Policy 2015-20, the Central Government hereby notifies a revised Appendix 4R under Para 4.59 of Foreign Trade Policy, 2015-20 for exports made from 15.12.2022.
2. The revised Appendix 4R will be applicable for exports made from 15.12.2022 to 30.09.2023. To adhere to the Scheme budgetary framework, necessary changes and revisions as per Para 4.54 of FTP 2015-20 (as amended from time to time) will be made thereafter.
3. The revised RoDTEP Appendix 4R containing the eligible RoDTEP export items, rates and per unit

value caps, wherever applicable is available at the DGFT portal www.dgft.gov.in under the link 'Regulatory Updates >RoDTEP'.

Effect of this Notification: Additional export sectors/items in Chapter 28, 29, 30 & 73 are being added in Appendix 4R under RoDTEP for exports made from 15.12.2022 and shall be applicable till 30.09.2023.

File No. 01/61/180/155/AM21/PC3

*Santosh Kumar Sarangi,
Director General of Foreign Trade,
Ex-officio Additional Secretary,
Ministry of Commerce & Industry,
Department of Commerce,
New Delhi.*



Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012 Amended (1st Amendment of 2022)

Notification S.O.5745(E), dated 8th December, 2022

In exercise of powers conferred by section 11 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), the Central Government hereby makes the following order further to amend the Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012, namely:-

1. Short title and commencement
 - (1) This order may be called the **Public Procurement Policy for Micro and Small Enterprises (MSEs) Amendment Order, 2022.**
 - (2) This order shall come into force on the date of its publication in the Official Gazette.
2. In the Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012, in the annexed

Order No.21(1)/2007-MA dated 21.06.2010, after sub-paragraph (iv) of paragraph 3, the following sub-paragraph shall be inserted, namely:-

“(v) Consider the requests of the Central Ministries/ Departments/PSUs for exemption, on a case to case basis, from procuring certain items from the reserved list for MSEs through open tendering”.

F.No.21(9)/2017-MA(Pt-I)

Vipul Goel, Development Commissioner, Ministry of Micro, Small and Medium Enterprises, New Delhi.

Note: The principal order was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii) vide number S.O.581(E), dated the 23rd March, 2012, subsequently amended vide number S.O.5670(E), dated the 9th November, 2018 and vide number S.O.3237(E), dated the 11th August, 2021.



In Lok Sabha & In Rajya Sabha

In Lok Sabha

Digitization of MSMEs

Lok Sabha Unstarred Question No. 232

Shrimati Aparajita Sarangi:

Q. Will the Minister of **MICRO, SMALL AND MEDIUM ENTERPRISES** be pleased to state:

- whether the schemes for digitization of MSMEs to boost business potential and to compete with other e-commerce large business have positively benefitted MSMEs;
- if so, the details for the reported number of MSMEs that have been digitized through the existing schemes for digitization of MSMEs;
- the data that indicates status of revenue and profitability of MSMEs after introduction of schemes to digitize MSMEs;
- whether the Government plans to introduce schemes that alleviate digital security concerns of MSMEs to incentivize more number of MSMEs to build an online presence and if so, the details thereof; and
- whether the Government is promoting any unified technology to ease digitization of MSMEs and if so, the details thereof?

Answered on 08th December, 2022

- A.** (a) & (b): The Government runs various programmers/ schemes to boost business potential and to compete with other e-commerce large business entities through various digitalization initiatives for MSMEs such as Udyam portal, MSME Champions Portal, Government e-Marketplace (GeM), Trade Receivables Discounting System (TReDS), msmemart.com. In addition, MSME SAMBANDH for monitoring of procurement by Central Public Sector Enterprises (CPSEs) from Micro and Small Enterprises (MSEs) and MSME SAMADHAAN portals for filling applications regarding delayed payments. As on date 1.24 crore MSMEs are registered in Udyam Registration portal and further benefitted through various programmes. Procurement from Central Ministries / Departments / CPSEs made purchases about Rs. 95576 Cr. from MSEs under Public Procurement Policy (PPP) for

MSEs and 21,360 applications filed by MSMEs have been disposed by MSEFC council.

(c): The information with respect to the status of revenue and profitability of MSMEs is not centrally maintained by Ministry of MSME.

(d) & (e): Under the MSME Champions Schemes 'Digital MSME' component has been included for digital empowerment of MSMEs in the country. The Ministry of MSME propose to support MSMEs through "Digital MSME" a component of MSME Champions Scheme to bring in digitization and digitalization and to make MSMEs digitally empowered and motivate them to adopt digital tools, applications and technologies in their production & business processes with a view to improve their competitiveness.

Minister of State for Micro, Small and Medium Enterprises (Shri Bhanu Pratap Singh Verma)

Participation of MSMEs in Global Market

Lok Sabha Unstarred Question No.360

Shri Girish Bhalchandra Bapat:

Dr. Pritam Gopinathrao Munde:

Shri Chandra Sekhar Sahu:

Shri Rahul Ramesh Shewale:

Q. Will the Minister of **MICRO, SMALL AND MEDIUM ENTERPRISES** be pleased to state:

- whether the Micro, Small and Medium Enterprises (MSMEs) sector in the country is the backbone of country's economic structure;
- if so, the facts thereof;
- whether the Union Government proposes to make more MSMEs competitive across the world to increase exports;
- if so, whether stronger participation of Indian MSMEs in the global markets can accelerate such a growth;
- if so, the details thereof and the steps taken by the Union Government in this regard;
- the present share of MSMEs in the country's export

and the extent to which the Union Government proposes to increase it during the next three years;

- (g) the initiatives/efforts being made by the Union Government to help MSMEs to take centre stage in the global space; and
- (h) whether any criteria has been fixed by the Union Government for classification of MSMEs to make these more competitive globally and if so, the details thereof?

Answered on 08th December, 2022

- A.** (a) & (b): The Micro, Small and Medium Enterprises (MSME) sector is the backbone of the Indian economy for its contribution to the growth of the Indian economy. As per information received from Ministry of Statistics & Programme Implementation, the Share of Gross Value Added (GVA) of MSME in All India GDP during 2019-20 and 2020-21 were 30.50% and 26.83% respectively.

(c) to (g): To enhance the competitiveness of MSMEs and increase their contribution in Indian exports, Government of India has taken various initiatives, namely, Make in India Programme, Promotion of Ease of Doing Business, improved availability of credit through MUDRA, Stand up India. Further, Ministry of MSME has established 52 Export Facilitation Centers (EFCs) across the country with an aim to provide requisite mentoring and handholding support to Micro and Small Enterprises (MSEs). Further, to make MSMEs more competitive and accelerate their growth in global markets, Ministry of MSME is providing assistance through various schemes namely, International Cooperation (IC) Scheme, MSME Champions Scheme, Cluster Development Programme, Credit linked Capital Subsidy Technology Upgradation Scheme (CLCS-TUS), Micro & Small Enterprises-Cluster Development Programme (MSECDP), Technology Centre System Program(TCSP), Procurement and Marketing Schemes (PMS) etc.

To increase competitiveness of MSMEs, a comprehensive B2B Portal- 'MSMEart.com' is being operated by the National Small Industries Corporation (NSIC) as a one stop digital solution to all business needs of MSMEs across all sectors and provide next generation services to MSMEs to make them competitive in global market. Further, Khadi & Village Industries Commission (KVIC) is also

implementing an e-commerce portal 'ekhadiindia.com' for B2C outreach, which enables businesses to have a global outreach.

The present share of MSME sector in the country's export is 45.03% (for FY 2021-22). Further, the two components under the IC Scheme namely, Market Development Assistance (MDA) component facilitating visit /participation of MSMEs in international exhibitions / trade fairs/ buyer-seller meet etc. abroad and also holding of International conferences/ seminars/workshops in India, as well as Capacity Building of First Time Exporters (CBFTE) component providing reimbursement of export related costs incurred by new MSE exporters, will inter-alia support MSME sector in their exports.

(h): No, Sir.

Minister of State for Micro, Small and Medium Enterprises (Shri Bhanu Pratap Singh Verma)

In Rajya Sabha

Ending use of single use plastic items

Rajya Sabha Unstarred Question No. 216

Smt. Kanta Kardam:

Q. Will the Minister of **ENVIRONMENT, FOREST AND CLIMATE CHANGE** be pleased to state:

- (a) whether the process of ending the use of the 20 identified single use plastic items, in a phased manner, from September 30, 2021 till date, is underway as per the scheduled programme;
- (b) whether the said list of identified single use plastic items also covers the larger part of the single use plastic pollution in the country which is to be curbed in a phased manner and;
- (c) if so, the details thereof and if not, the reasons therefor?

Answered on 08th December, 2022

- A.** (a) The Ministry of Environment, Forest and Climate Change has notified the Plastic Waste Management Amendment Rules, 2021, on 12th August 2021, prohibiting manufacture, import, stocking, distribution, sale and use of the following identified single use plastic items, which have low utility and high littering potential with effect from 1st July, 2022:

- (i) ear buds with plastic sticks, plastic sticks for balloons, plastic flags, candy sticks, icecream sticks, polystyrene [Thermocol] for decoration;
- (ii) plates, cups, glasses, cutlery such as forks, spoons, knives, straw, trays, wrapping or packing films around sweet boxes, invitation cards, and cigarette packets, plastic or PVC banners less than 100 micron, stirrers.

The notification also prohibits manufacture, import, stocking, distribution, sale and use of plastic carry bags having thickness less than seventy-five microns with effect from 30th September 2021, and having thickness less than thickness of one hundred and twenty microns with effect from the 31st December, 2022.

(b) and (c): The single use plastic items prohibited with effect from 1st July 2022 were identified by the Expert Committee constituted by Department of Chemical and Petrochemicals, Government of India based upon their high littering potential and low utility.

Littered and unmanaged plastic waste contributes towards environmental pollution. Therefore, prohibition on such single use plastic items will help in reducing pollution caused due to littered and unmanaged plastic waste.

**Minister of State in the Ministry of Environment,
Forest and Climate Change
(Shri Ashwini Kumar Choubey)**

Ban on single use plastic

Rajya Sabha Unstarred Question No. 195

Shri V. Vijayasai Reddy:

Q. Will the Minister of **ENVIRONMENT, FOREST AND CLIMATE CHANGE** be pleased to state:

- (a) impact of banning single use plastic on industries that are manufacturing single-use plastic products;
- (b) whether Ministry has sent any proposal to the Minister of Finance or the GST Council to reduce GST on raw material used for manufacturing alternatives to single use plastic products;
- (c) if so, the details thereof; and
- (d) if not, whether the Ministry will send such a proposal now?

Answered on 08th December, 2022

- A.** (a) to (d): The prohibition on identified single use plastic items was notified on 12th August 2021 and it came into effect from 1st July 2022. Transition time was provided to units manufacturing banned single use plastic to shift to alternatives. The Ministry of Micro, Small and Medium Enterprises has schemes to provide support to MSME units, which include support to such units earlier involved in manufacturing of banned single use plastic items for switching over to alternatives / other products. These schemes provide support in respect of technology upgradation, creating awareness, marketing support, infrastructural support, as per scheme guidelines. The manufacturing of alternatives will create new job opportunities and business models. GST Council secretariat has been suggested to adjust the GST rates in order to increase adoption of alternatives to banned single use items.

**Minister of State in the Ministry of Environment,
Forest And Climate Change
(Shri Ashwini Kumar Choubey)**

Proposal for Reduction of Imports from China

Rajya Sabha Unstarred Question No. 374(H)

Shri Narain Dass Gupta:

Q. Will the Minister of **COMMERCE & INDUSTRY** be pleased to state:

- (a) the quantum and details of goods imported from China during the Financial Years 2018-19 to 2021-22, the year-wise details thereof;
- (b) whether there has been a decrease in exports relative to imports from China, if so, the proportion thereof;
- (c) whether Government is developing any proposal to reduce the imports from China;
- (d) if so, the details thereof; and
- (e) if not, the reasons therefor?

Answered on 09th December, 2022

- A.** (a) & (b): The year-wise details of import and export of goods from China are as follows:

Values in USD Billion

Year	Import	Export
2018-19	70.32	16.75
2019-20	65.26	16.61
2020-21	65.21	21.19
2021-22	94.57	21.26

Source: DGCI&S, Kolkata

Many imports are inputs for further manufacturing in India and exports from India. The major goods imported from China include electronic goods, organic and inorganic chemicals, medicinal and pharmaceutical products, fertilisers, crude and manufactured and dyeing/tanning/colouring materials.

(c) to (e): Most of the goods imported from China are capital goods, intermediate goods and raw materials and are used for meeting the demand of fast expanding sectors like electronics, telecom and power in India. India's dependency on imports in these categories is largely due to the gap between domestic supply and demand.

The Government has launched Production Linked Incentive (PLI) schemes to make Indian manufacturers globally competitive, attract investment in the areas of core competency/cutting-edge technology, enhance exports, integrate India in global supply chain and reduce dependency on imports.

Technical Regulations (TRs) have been framed for several products for maintenance of standards/quality of imported products. Several trade remedial actions have been taken against imports from China to protect the domestic industry from serious injury (Anti-Dumping measures in force-53, Countervailing Duty measures in force-4) against unfair trade.

The Minister of State in the Ministry of Commerce and Industry (Smt. Anupriya Patel)

India China trade relationship

Rajya Sabha Starred Question No. 31

Shri Digvijaya Singh:

Q. Will the Minister of **COMMERCE & INDUSTRY** be pleased to state:

- whether it is a fact that China is India's largest trade partner;
- the value of goods traded with China, including details of imports and exports, year-wise from Financial Year 2019 till date;
- the details of India's trade deficit with China, year-wise from Financial Year 2019 till date;
- the reasons for India's increasing reliance on Chinese imports for capital goods and Intermediate goods; and
- the reasons for India remaining dependent on Chinese imports for chemicals and electronics despite PLI schemes for the same?

Answered on 09th December, 2022

A. (a) to (e): A Statement is laid on the Table of the House.

**The Minister of Commerce and Industry
(Shri Piyush Goyal)**

Statement Referred to in Reply to Parts (A) to (E) of Rajya Sabha Starred Question No. 31 for Answer on 09th December, 2022 Regarding "India China Trade Relationship".

- No. The largest merchandise trading partner of India in 2021-22 was United States of America.
- The merchandise exports from India to China have increased from USD 11.93 billion in 2014-15 to USD 21.26 billion in 2021-22, showing an increase of 78.2 % over the last six years. The merchandise imports from China have increased from USD 60.41 billion in 2014-15 to USD 94.57 billion in 2021-22, showing an increase of 56.54 % over 2014-15. The growth in imports from China in this period have declined compared to the period prior to 2014. Imports had increased from USD 7.10 billion in 2004-05 to USD 51.03 billion in 2013-14 exhibiting increase of 618%.
- The trade deficit with China since FY 2014-15 is as follows:

(Values in USD billion)

FY	2014- 15	2015- 16	2016- 17	2017- 18	2018- 19	2019- 20	2020-21	2021- 22	2022-23 (Apr- Oct) (P)
Export	11.93	9.01	10.17	13.33	16.75	16.61	21.18	21.26	8.77
Import	60.41	61.70	61.28	76.38	70.31	65.26	65.21	94.57	60.27
Total trade	72.34	70.71	71.45	89.71	87.06	81.87	86.39	115.83	69.04
Trade Deficit	48.48	52.69	51.11	63.05	53.56	48.65	44.03	73.31	51.50

(Source: DGCIS)

*(P) is for provisional

The trade deficit with China in 2004-05 was USD 1.48 billion, which increased to USD 36.21 billion in 2013-14, an increase of 2346%. Against this massive increase, the trade deficit with China has since increased by only 100% to USD 73.31 billion in 2021-22.

- (d) Most of the goods imported from China are capital goods, intermediate goods and raw materials and are used for meeting the demand of fast expanding sectors like electronics, telecom and power in India. The rise in import of electronic components, computer hardware and peripherals, telephone components, etc. can be attributed to transforming of India into a digitally empowered society and a knowledge economy. India's dependence on imports in these categories is largely due to the gap between domestic supply and demand.
- (e) The raw materials in form of Active Pharmaceutical Ingredients (APIs) and drug formulations imported from China are used for making finished products (generic medicines) which are also exported out of India. The electronic components such as mobile phone parts, integrated circuits, video recording or reproducing apparatus etc are used for making finished products (e.g. mobile handsets) which are also exported to other countries. The PLI schemes in API/Bulk Drugs/Key Starting Materials and Large-Scale Electronics Manufacturing have been launched by the Government recently and have started delivering results. The PLI schemes will reduce dependency on imports and make India a competitive destination for drugs/electronics manufacturing and create more domestic champions apart from giving boost to Atmanirbhar Bharat.

The PLI schemes have started showing results and some examples are enumerated below:

- i) PLI Scheme for Large Scale Electronics Manufacturing was notified on 1st April 2020 with targeted segments being mobile phones and specified electronic components. The PLI Scheme for Large Scale Electronics Manufacturing has attracted large investments from global and domestic companies manufacturing mobile phones and specified electronic components. The production as well as exports of mobile phones have increased. The imports of mobile handsets have decreased from Rs 48,609 crore in FY 2014-15 to around Rs 11,209 crore in FY 2021-22 whereas the Mobile phone exports from India touched the USD 1 billion mark (over ₹8,200 crore) for the first time ever in September 2022. In FY 2022-23, mobile phone exports have increased more than USD 5 billion till October 2022 against USD 2.2 billion in 2021-22 during the same period. PLI as an instrument has reduced India's dependency on China.
- ii) Under PLI for API, a total of 51 applicants have been approved with a committed investment of Rs.4138.41 crore and expected employment generation of around 10,598 persons. Industry has responded well and the actual investment up to September 2022 is Rs.1707.37 crore
- (iii) Under PLI Scheme for 'Medical Devices', total 21 applicants have been approved, with a total committed investment of Rs. 1058.97 crore.
- (iv) Under PLI for Pharmaceuticals, 55 applications have been approved with total committed expenditure

of Rs.17,425 crore and actual investment up to September 2022 is Rs.15,164 crore with 261 manufacturing location commissioned.

- (v) Under PLI for Telecom and Networking Products, in order to facilitate Design-led manufacturing for 5G products and to enhance the scope of the scheme, amendments were made in the PLI Scheme Guidelines with effect from 01-04-2022. Approval has been granted to 42 companies, including 28 MSMEs, under the scheme, out of which 17 companies have applied for additional incentive of 1% under design-led manufacturing criteria. These 42 companies have committed investment of Rs. 4,115 crores over the scheme period. For Telecom and Networking products, as on 30-09-2022, there is sale of Rs.14,735crores with export of Rs.8,063 Crores since 01-04-2021.

- (vi) Under PLI scheme for High efficiency Solar PV modules, under tranche 1 of scheme, letter of awards has been issued to 3 successful bidders in Nov./Dec 2021 for setting up 8.737 GW capacity of fully integrated solar PV module manufacturing units which involve setting up of manufacturing units for polysilicon, ingots-wafers, cells and modules. The manufacturing capacity is scheduled for commissioning around end of 2024.

The PLI schemes have been rolled out and the manufacturing units are in the process of setting up capacities. Good results are already visible in sectors like mobile phones, and we would see positive developments in the other sectors in the recent times also.



NOW AVAILABLE ! IDMA-APA GUIDELINES / TECHNICAL MONOGRAPHS

TECHNICAL MONOGRAPH NO. 1
**STABILITY TESTING OF EXISTING
DRUGS SUBSTANCES AND PRODUCTS**

TECHNICAL MONOGRAPH NO. 3
**INVESTIGATION OF OUT OF SPECIFICATION
(OOS) TEST RESULTS**

TECHNICAL MONOGRAPH NO. 5
**ENVIRONMENTAL MONITORING
IN CLEANROOMS**

TECHNICAL MONOGRAPH NO. 7
DATA INTEGRITY GOVERNANCE

TECHNICAL MONOGRAPH NO. 2
**PRIMARY & SECONDARY CHEMICAL
REFERENCE SUBSTANCES**

TECHNICAL MONOGRAPH NO. 4
**PHARMACEUTICAL PREFORMULATION
ANALYTICAL STUDIES**

TECHNICAL MONOGRAPH NO. 6
**CORRECTIVE/PREVENTIVE ACTIONS
(CAPA) GUIDELINE**

TECHNICAL DOCUMENT NO. 8
**QUALITY 4.0 DIGITAL
TECHNOLOGY OF THE FUTURE**

Copies are available at IDMA Office, Mumbai. We do not mail any publications against VPP payment.
All payments to be made in advance as Cheque/DD/RTGS/NEFT in favour of "**INDIAN DRUG
MANUFACTURERS' ASSOCIATION**" at Mumbai.

For more details please contact: **PUBLICATIONS DEPARTMENT** Tel.: 022 - 2494 4624 / 2497 4308 Fax: 022 - 2495 0723
E-mail: publications@idmaindia.com/actadm@idmaindia.com, Website: www.idma-assn.org/www.indiandrugsonline.org

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed



The domestic pharmaceutical market saw its highest growth rate for 2022 in November, at 17.3 per cent, after both volume sales and price growth picked up.

Compared to November 2021, when it had clocked 6.6 per cent growth, the Indian Pharmaceutical Market (IPM) posted robust growth numbers last month as anti-infective therapy drove the market demand.

Volume growth had slowed in the months of February, March, April, and May, indicating that unit sales in the IPM were declining. The overall IPM growth was in negative territory for these four months.

A gradual rebound started in June, but in October again, volume sales declined by 0.9 per cent.

Explaining the trend, Sheetal Sapale, president (marketing) at pharma market research company AWACS, said anti-infective therapy sales were quite high and did not match the seasonal pattern. "If you were to look at

the growth drivers for November last year, the volume growth was zero. So, the 17 per cent growth is a result of two things – one is low volume growth in November 2021, and a revival in sales growth after a dip in October 2022," she said.

Sapale said that apart from anti-infective therapy, no major therapy had shown an aberration in demand. She said a lot of pending surgeries were happening now. "Therefore, in the anti-infective therapy segment, hospital anti-infectives are driving demand," she added.

Anti-infectives – antibiotics, antivirals, antifungals etc -- clocked 15 per cent growth in November.

This therapy is Rs 22,280 crore in size annually. In November alone, Rs 2077 crore worth of anti-infective drugs were sold, compared to Rs 2,075 crore of cardiac drugs, Rs 1,460 crore of anti-diabetic drugs.

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed.

Anti-diabetic, cardiac, respiratory, vitamins, and gynaecological therapies posted strong double-digit numbers during the month.


Among corporates, Alkem, Aristo, Glenmark, Intas, and Abbott clocked strong growth rates of above 20 percent during the month. Market leader Sun Pharma clocked 15 per cent growth in sales, while Cipla (17 per cent), Zydus (20 per cent) and Mankind (19 per cent) also posted strong growth.

Cipla witnessed 20 per cent volume growth during the month.

Will this growth trend continue?

"Typically long-term growth in the domestic market is driven by chronic therapies. The good news is, in the last few months, thanks to patent expiries etc, the chronic therapies of cardiac and antidiabetic have done well. November growth is riding on acute therapy anti-infectives, which may taper in the coming months," said the cardio-diabetic division head of a Mumbai-based mid-sized firm.

Source: Sohini Das, Business Standard, 08.12.2022



Saudi Arabia invites Indian cos to supply 300 life-saving drugs in therapeutic segments like AIDS, TB, BP, etc

Indian pharmaceutical companies are planning to supply drugs to Saudi Arabia in therapeutic segments like AIDS, TB, Hypertension, infectious diseases, bacterial infections and mental illness among others.

These key therapeutic segments have been covered as part of the 300 life-saving drugs list shared with the Indian Drug Manufacturers Association (IDMA) by the Saudi Food and Drugs Authority (SFDA), Kingdom of Saudi Arabia for which the latter has invited the Indian companies to supply drugs based on the local requirement.

The list of drugs include dexamethasone which is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, amlodipine, which is used to treat high blood pressure, ampicillin and sulbactam combination used to treat bacterial infections, atazanavir, an antiretroviral medication used to treat HIV/AIDS, atenolol used to treat high blood pressure and heart-associated chest pain, lamivudine which is used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2.

The list includes amitriptyline used to treat symptoms of depression and H1N1 influenza vaccine inactivated, lipase-protease-amylase digestive enzymes to help break down and digest fats, starch, and proteins in food.

Antibiotics like isoniazid used for the treatment of tuberculosis, carbamazepine to control certain types of seizures in people with epilepsy, azithromycin used to treat certain bacterial infections, such as bronchitis, pneumonia, sexually transmitted diseases (STD), and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs and artesunate injection used to treat severe malaria is also in the list.

Saudi Arabia had a market size of \$7.8 billion in 2021 for pharmaceuticals which includes patented drugs of about \$4.13 billion, generics at \$2.87 billion and over-the-counter (OTC) drugs of \$780 million.

Pharmabiz has reviewed the letter and the list of the drugs specified in it which states, "Saudi Food and Drugs

Authority (SFDA), Kingdom of Saudi Arabia is inviting Indian Drugs and Pharmaceuticals manufacturers to participate in achieving drug security in the Kingdom of Saudi Arabia."

"Due to technical or regulatory issues, availability of inputs in manufacturing faces problems in the Kingdom of Saudi Arabia. Executive Directorate for Regulatory Affairs in Drugs department of SFDA will be happy to resolve these issues in consultation with the respective company," the letter said.

"We have therefore requested interested members to fill out the attached form given in the excel sheet along with the list of products that they may like to register in the Kingdom and also specify the support required by their company. There are a number of pharmaceutical products that are not present in the Kingdom despite the local market's requirement for them. The authority has prepared the list and prepared a package of incentives and facilities, and they are pleased to invite the Indian drug manufacturers to apply for the registration of the drugs mentioned in the attached list according to the mechanism mentioned in the list," said IDMA secretary general Daara Patel.

Source: Shardul Nautiyal, Pharmabiz, 14.12.2022



Goyal meets UK trade secy to give momentum to FTA talks



Union Minister of Commerce Piyush Goyal with UK Trade Secretary Kemi Badenoch in New Delhi on Tuesday. PTI

Commerce Minister Piyush Goyal and his UK counterpart Kemi Badenoch on Tuesday reviewed the

progress of talks for the proposed free trade agreement (FTA). The UK Trade Secretary is here to kick-start the sixth round of FTA negotiations and hold bilateral talks with Goyal.

The negotiations, the first under the Rishi Sunak government, are taking place after a gap of more than four months.

The UK side is believed to be pressing for a cut in import duty, especially on automobiles and Scotch whisky, besides easing of the Indian intellectual property regime. India, on the other hand, is aiming for elimination of customs duty in labour-intensive sectors such as textiles, leather, gems and jewellery as well as easier mobility for its skilled professionals.

Recently, India and Australia exchanged written notifications on the signing of the Economic Cooperation

and Trade Agreement (India-Australia ECTA), which will enter into force from December 29. Bilateral trade is expected to cross \$45-50 billion in five years from the existing \$31 billion.

India's main exports to the UK include ready-made garments and textiles, gems and jewellery, engineering goods, petroleum and petrochemical products, transport equipment and parts, spices, metal products, machinery and instruments, pharma and marine items.

Major imports include precious and semi-precious stones, ores and metal scraps, engineering goods, professional instruments, non-ferrous metals, chemicals and machinery.

Source: Tribune News Service, 13.12.2022



**For Advertising in the Classified Columns and also for series advertisements please contact:
Geeta Suvarna (+9820161419)
Publications Department**

IDMA BULLETIN

Tel.: 022 - 2494 4624 / 2497 4308 /
Fax: 022 - 2495 0723/
E-mail: publications@idmaindia.com,
Website: www.idma-assn.org,
www.indiandrugsonline.org



Have you renewed your Membership for the years

2021-2022 & 2022-2023

If not, please do so; kindly contact
IDMA Secretariat at:

Email: actadm@idmaindia.com /
accounts@idmaindia.com

Tel.: 022 - 2494 4624 / 2497 4308 /
Fax: 022 - 2495 0723



IDMA BULLETIN

PUBLISHED ON 7th, 14th, 21st and 30th of Every Month

ADVERTISEMENT TARIFF

(Effective from 01.11.2017)

Magazine Size: 21.5 cm x 27.5 cm / Print Area: 18.5 cm x 23.5 cm

Position		Rate per Insertion ₹	
		B/W	Colour
Full Page (18 cm wd x 23.5 cm ht)	:	9,000	12,500
Half Page (18 cm wd x 11.5 cm ht) (Horizontal)		5,000	8,500
Half Page (8.5 cm x 23.5 cm) (Vertical)	:	5,000	8,500
Quarter Page (8.5 cm wd x 11.5 cm ht)	:	2,500	6,000
Strips Advts (4 cm ht x 18 cm wd)	:	2,500	-
Inside Cover Pages	:	-	18,000
Back Cover	:		25,000
Centre Spread (double spread) Print area (40cm wd x 27cm ht)	:	25,000	30,000

Terms and Conditions:

- All payments by **Cheque/ Demand Draft/RTGS** in advance only to be made in favour of “Indian Drug Manufacturers’ Association”, Payable at Mumbai

The RTGS details are as follows:- BANK: BANK OF BARODA

Account Name : **Indian Drug Manufacturers’ Association**, Bank A/c No. : Current A/c **7608020000242**

Bank : **BANK OF BARODA**, Branch Address : Worli Branch, Mumbai-18, **IFSC : BARB0DBWOL**

MICR CODE : 400012232

- GST will be charged extra, as applicable. (Current Rate is @5%)
- SPECIAL DISCOUNTS for Series Advertisements
- For colour advertisements, positives to be supplied otherwise processing charges to be paid.
- Advertisement material must reach us 7 days before the date of publication.**
- Positioning of the Advt other than Cover Positions will be at our discretion.
- Only Colour Advts will be entertained on Cover Positions.

Classified Advertisements

- Upto 80 words — ₹2,000/-
- 50% extra for Advt Box Number
- 50% extra for indent/layout spacing, bold captions, etc.
- ₹50/- extra for voucher copy
- Series discount not applicable for classifieds

For further details such as series discounts etc, please contact:

Melvin Rodrigues — Cell: +9821868758 (Email: actadm@idmaindia.com)/

Geeta Suvarna — Cell: +9820161419 (Email: publications@idmaindia.com)

PUBLICATIONS DIVISION

INDIAN DRUG MANUFACTURERS’ ASSOCIATION

102-B, Poonam Chambers, Dr. A. B. Road, Worli, Mumbai 400 018. Tel: 022-2494 4624/2497 4308 Fax: 022-2495 0723

Website: www.idma-assn.org/www.indiandrugsonline.org

INFINITE APPLICATIONS. **ONE IDENTITY.**

Dear Partner,

For over three decades, we have been dedicating ourselves to the pharmaceutical excipients industry in India. Three decades of relentless effort that has become our identity.

Today, that effort is evident in hundreds of applications across the arena of pharma, nutra and biopharma. And we are renewing our pledge to further enforce our efforts by focusing on one area - excipients. So we can continue to serve the industry and our partners even better, with greater efficiency and deeper integration.

Because while what we do leads to infinite ends, our identity remains uniquely unchanged - excipients.

Signet-ure

Identity

Signet

The Complete Excipients Company






Introducing PureHale From Aptar Pharma

PureHale is an industry first, a portable and ready-to-use nebulizer-like device designed to deliver natural care to upper airways.

When used in combination with saline water and other natural ingredient formulations, PureHale helps to relieve symptoms for upper airway conditions such as coughs, colds, allergies, respiratory problems, dry nose and throat and other irritations.

To find out more about how PureHale can make better breathing easy, contact **Guenter Nadler**, Business Development Director at Aptar Pharma on **+49 7732 801 536** or email guenter.nadler@aptar.com



Delivering solutions, shaping the future.

Aptar 
pharma